PURE Bioscience, Inc.
Income Statement
| Line Item | Apr 2026 | Jan 2026 | Oct 2025 | Jul 2025 | Apr 2025 | Jan 2025 | Oct 2024 | Jul 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $506.0K | $443.0K | $707.0K | $763.0K | $489.0K | $391.0K | $555.0K | $472.0K |
| Cost of Revenue | $237.0K | $206.0K | $258.0K | $296.0K | $208.0K | $164.0K | $231.0K | $199.0K |
| Gross Profit | $269.0K | $238.0K | $450.0K | $468.0K | $283.0K | $227.0K | $325.0K | $275.0K |
| Gross Margin | 53.2% | 53.7% | 63.6% | 61.3% | 57.9% | 58.1% | 58.6% | 58.3% |
| Operating Expenses | ||||||||
| Research & Development | $79.0K | $74.0K | $86.0K | $73.0K | $91.0K | $81.0K | $71.0K | $69.0K |
| SG&A Expense | $708.0K | $847.0K | $743.0K | $731.0K | $776.0K | $871.0K | $881.0K | $845.0K |
| Operating Income | $-518.0K | $-683.0K | $-379.0K | $-336.0K | $-584.0K | $-725.0K | $-627.0K | $-699.0K |
| Operating Margin | -102.4% | -154.2% | -53.6% | -44.0% | -119.4% | -185.4% | -113.0% | -148.1% |
| Interest Expense | — | — | $91.0K | — | — | — | $60.0K | $40.0K |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-624.0K | $-785.0K | $-464.0K | $-332.0K | $-580.0K | $-798.0K | $-689.0K | $-756.0K |
| Net Margin | -123.3% | -177.2% | -65.6% | -43.5% | -118.6% | -204.1% | -124.1% | -160.2% |
| EPS (Basic) | $-0.01 | $-0.01 | $0.00 | $0.01 | $-0.01 | $-0.01 | $-0.01 | $0.00 |
| EPS (Diluted) | $-0.01 | $-0.01 | $0.00 | $0.01 | $-0.01 | $-0.01 | $-0.01 | $0.00 |
| Shares Outstanding (Basic) | 110.8M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M |
| Shares Outstanding (Diluted) | 110.8M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M | 111.9M |
| Dividends Per Share | — | — | — | — | — | — | — | — |